Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
Funds will support UK commercial launch and FDA 510(k) submission later this year
The combined companies will have revenue drivers of two commercially available diagnostics tools, Cologuard and Oncotype DX.
The new company will be helmed by Mylan’s Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
Gemphire will enter into the reverse merger following a strategic review of its options.
MorphoSys AG will publish its first six months’ 2019 results on August 6, 2019 at 10:00pm CEST.
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Alphora Research Inc. to support Eurofins’ extensive drug development platform.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Amatsigroup SAS to support Eurofins’ extensive drug development platform.